Moderna had its best day ever after it and Merck reported positive topline Phase 3 results, where a personalized mRNA therapy added to Keytruda improved recurrence free survival in patients whose melanoma had already been surgically removed. It is the first positive Phase 3 readout for an mRNA cancer therapy. Detailed efficacy figures have not been released. About $1.9 million in call premium hit the tape behind it, split between one contract with a month of runway and one expiring in two days. With roughly 13 percent of the float short going in, much of the move was forced buying. 📊 tastylive: tastylive.com 📰 Get Tom's pre-market analysis every morning: tastylive.com/newsletters 📘 FREE Options Strategy Guide: tinyurl.com/bp9ms763 📱 Follow tastylive on X: x.com/tastyliveshow Chapters 00:00 The news that moved Moderna 00:42 What the trial actually showed 01:15 Wall Street was positioned wrong 02:02 A heavily shorted float 02:34 The two tra...